Literature DB >> 19692700

How I treat hypereosinophilic syndromes.

Amy D Klion1.   

Abstract

Hypereosinophilic syndromes (HESs) are a heterogeneous group of uncommon disorders characterized by marked peripheral eosinophilia and end organ manifestations attributable to the eosinophilia or unexplained in the clinical setting. Whereas corticosteroids remain the mainstay of treatment for most patients, recent diagnostic advances and the development of novel targeted therapies, including tyrosine kinase inhibitors and humanized monoclonal antibodies, have increased the complexity of therapeutic decisions in HESs. This review presents a treatment-based approach to the diagnosis and classification of patients with peripheral blood eosinophilia of 1.5 x 10(9)/L (1500/mm3) or higher and discusses the role of currently available therapeutic agents in the treatment of these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19692700      PMCID: PMC2773488          DOI: 10.1182/blood-2009-07-143552

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.

Authors:  Vincenzo Pitini; Carmela Arrigo; Domenico Azzarello; Gaetana La Gattuta; Cinzia Amata; Maria Righi; Sebastiano Coglitore
Journal:  Blood       Date:  2003-11-01       Impact factor: 22.113

2.  Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.

Authors:  Sabine-Gisela Plötz; Hans-Uwe Simon; Ulf Darsow; Dagmar Simon; Ekatherina Vassina; Shida Yousefi; Rüdiger Hein; Tim Smith; Heidrun Behrendt; Johannes Ring
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

3.  Clinical and immunological features of patients with interleukin-5-producing T cell clones and eosinophilia.

Authors:  H U Simon; S G Plötz; D Simon; R Dummer; K Blaser
Journal:  Int Arch Allergy Immunol       Date:  2001 Jan-Mar       Impact factor: 2.749

4.  Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.

Authors:  Amy D Klion; Pierre Noel; Cem Akin; Melissa A Law; D Gary Gilliland; Jan Cools; Dean D Metcalfe; Thomas B Nutman
Journal:  Blood       Date:  2003-04-03       Impact factor: 22.113

5.  Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia.

Authors:  L Schandené; F Roufosse; A de Lavareille; P Stordeur; A Efira; B Kennès; E Cogan; M Goldman
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

6.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

7.  Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome.

Authors:  F Roufosse; L Schandené; C Sibille; K Willard-Gallo; B Kennes; A Efira; M Goldman; E Cogan
Journal:  Br J Haematol       Date:  2000-06       Impact factor: 6.998

8.  Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.

Authors:  Amy D Klion; Jamie Robyn; Cem Akin; Pierre Noel; Margaret Brown; Melissa Law; Dean D Metcalfe; Cynthia Dunbar; Thomas B Nutman
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

9.  Imatinib for systemic mast-cell disease.

Authors:  A Pardanani; M Elliott; T Reeder; C Y Li; E J Baxter; N C P Cross; A Tefferi
Journal:  Lancet       Date:  2003-08-16       Impact factor: 79.321

10.  Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.

Authors:  Animesh Pardanani; Terra Reeder; Luis F Porrata; Chin-Yang Li; Henry D Tazelaar; E Joanna Baxter; Thomas E Witzig; Nicholas C P Cross; Ayalew Tefferi
Journal:  Blood       Date:  2002-12-27       Impact factor: 22.113

View more
  15 in total

Review 1.  FIP1L1/PDGFR alpha-associated systemic mastocytosis.

Authors:  Yoshiyuki Yamada; Jose A Cancelas
Journal:  Int Arch Allergy Immunol       Date:  2010-06-04       Impact factor: 2.749

Review 2.  Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.

Authors:  Peter Valent; Gerald J Gleich; Andreas Reiter; Florence Roufosse; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Karl Sotlar; Joseph H Butterfield; Sabine Cerny-Reiterer; Matthias Mayerhofer; Peter Vandenberghe; Torsten Haferlach; Bruce S Bochner; Jason Gotlib; Hans-Peter Horny; Hans-Uwe Simon; Amy D Klion
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

Review 3.  Biological Modulators in Eosinophilic Diseases.

Authors:  Panida Sriaroon; Mark Ballow
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

4.  Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome.

Authors:  Grzegorz Helbig; Marek Hus; Magdalena Hałasz; Marek Dudziński; Agnieszka Więcławek; Małgorzata Stachowicz; Anna Soja; Sławomira Kyrcz-Krzemień
Journal:  Med Oncol       Date:  2011-01-22       Impact factor: 3.064

Review 5.  Clinical overview of cutaneous features in hypereosinophilic syndrome.

Authors:  Sabine Gisela Plötz; Bettina Hüttig; Birgit Aigner; Christian Merkel; Knut Brockow; Cezmi Akdis; Ulf Darsow; Johannes Ring
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

Review 6.  Targeting eosinophils in allergy, inflammation and beyond.

Authors:  Patricia C Fulkerson; Marc E Rothenberg
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

7.  Complex hypereosinophilia arising from post-polycythemia vera myelofibrosis: A case of imatinib-responsiveness.

Authors:  Ryan D Gentzler; Alex C Minella; Brady L Stein
Journal:  Leuk Res Rep       Date:  2012-11-10

8.  ICON: Eosinophil Disorders.

Authors:  Peter Valent; Amy D Klion; Lanny J Rosenwasser; Michel Arock; Bruce S Bochner; Joseph H Butterfield; Jason Gotlib; Torsten Haferlach; Andrzej Hellmann; Hans-Peter Horny; Kristin M Leiferman; Georgia Metzgeroth; Kenji Matsumoto; Andreas Reiter; Florence Roufosse; Marc E Rothenberg; Hans-Uwe Simon; Karl Sotlar; Peter Vandenberghe; Peter F Weller; Gerald J Gleich
Journal:  World Allergy Organ J       Date:  2012-12       Impact factor: 4.084

Review 9.  Hypereosinophilic Syndrome.

Authors:  Casey Curtis; Princess Ogbogu
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 10.817

10.  Eosinophils affect functions of in vitro-activated human CD3-CD4+ T cells.

Authors:  Issam Harfi; Liliane Schandené; Sarah Dremier; Florence Roufosse
Journal:  J Transl Med       Date:  2013-05-06       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.